Table 3.

Log-rank Mantel-Cox analysis of clinical parameters in survival in CRC patients.

Variables		No. total	No. events	Mean survival	95% CI	p-value
Sex	Male	192	65	72.0	66.2–77.7	0.927
	Female	147	48	73.4	66.6–80.1
Age	≤ 66 ys	164	55	73.4	67.1–79.6	0.755
	> 66 ys	175	58	71.6	65.4–77.8
Tumor status	T1+2	97	18	84.5	77.4–91.6	0.001
	T3	228	87	67.6	62.1–73.1
	T4	14	8	60.6	40.1–81.2
Nodal status	N0	176	37	84.4	79.2–89.6	<0.001
	N1	101	44	62.4	54.1–70.7
	N2	62	32	53.6	42.3–65.0
Metastasis status	M0	328	107	73.4	68.8–77.8	0.089
	M1	11	6	51.9	25.2–78.7
Clinical stage	I	76	10	86.3	79.7–92.9	<0.001
	II	98	26	80.4	73.2–87.7
	III	154	71	58.7	51.8–65.7
	IV	11	6	51.9	25.1–78.7
HLA-G (mAb 4H84)	Neg	98	29	76.7	69.0–84.5	0.250
	Pos	241	84	70.7	65.4–76.0
HLA-G (mAb 5A6G7)	Neg	142	54	69.5	62.9–76.2	0.268
	Pos	197	59	74.9	69.0–80.8
ΔHLA-G status*
	ΔHLA-Gneg	57	10	87.9	79.4–96.4	0.017
	ΔHLA-Gcom	143	48	71.0	64.0–77.9
	ΔHLA-Gpos	139	55	67.2	60.3–74.1
4H84neg5A6G7pos	/	40	8	85.5	74.8–96.2	0.046
4H84pos5A6G7neg	/	84	33	68.1	59.2–77.0

^*_ΔHLA-G: the difference of the percentage of HLA-G expression detected with mAb 4H84 subtracted that with mAb 5A6G7. _ΔHLA-G_neg:ΔHLA-G >−5.0%; _ΔHLA-G_com:−5.0%≤_ΔHLA-G≤5.0%; _ΔHLA-G_pos: _ΔHLA-G > 5.0%.